- Home
- BUJA vs CMRX Comparison
BUJA vs CMRX Comparison
Compare BUJA & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- CMRX
- Stock Information
- Founded
- BUJA 2022
- CMRX 2000
- Country
- BUJA Malaysia
- CMRX United States
- Employees
- BUJA N/A
- CMRX N/A
- Industry
- BUJA Blank Checks
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- BUJA Finance
- CMRX Health Care
- Exchange
- BUJA Nasdaq
- CMRX Nasdaq
- Market Cap
- BUJA N/A
- CMRX 77.0M
- IPO Year
- BUJA 2023
- CMRX 2013
- Fundamental
- Price
- BUJA $10.96
- CMRX $0.93
- Analyst Decision
- BUJA
- CMRX Strong Buy
- Analyst Count
- BUJA 0
- CMRX 1
- Target Price
- BUJA N/A
- CMRX $11.00
- AVG Volume (30 Days)
- BUJA 2.7K
- CMRX 119.4K
- Earning Date
- BUJA 01-01-0001
- CMRX 11-08-2024
- Dividend Yield
- BUJA N/A
- CMRX N/A
- EPS Growth
- BUJA N/A
- CMRX N/A
- EPS
- BUJA 0.29
- CMRX N/A
- Revenue
- BUJA N/A
- CMRX $144,000.00
- Revenue This Year
- BUJA N/A
- CMRX $3,040.12
- Revenue Next Year
- BUJA N/A
- CMRX N/A
- P/E Ratio
- BUJA $37.13
- CMRX N/A
- Revenue Growth
- BUJA N/A
- CMRX N/A
- 52 Week Low
- BUJA $10.30
- CMRX $0.75
- 52 Week High
- BUJA $12.18
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- BUJA 67.66
- CMRX 60.78
- Support Level
- BUJA $10.85
- CMRX $0.80
- Resistance Level
- BUJA $10.85
- CMRX $0.98
- Average True Range (ATR)
- BUJA 0.00
- CMRX 0.05
- MACD
- BUJA -0.00
- CMRX 0.01
- Stochastic Oscillator
- BUJA 87.50
- CMRX 83.33
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.